HCPCS Level II J9010: Injection, alemtuzumab, 10 mg
HCPCS Level II code J9010 represents an injection of alemtuzumab, 10 mg used for systemic administration; the service is a therapeutic monoclonal antibody infusion/injection typically delivered in an infusion center or hospital outpatient setting for treatment of certain hematologic or oncologic conditions.
Customize your policy alerts
Sign up for hcpcs J9010 policy alerts
Get alerted when payer policies referencing J9010 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial national benchmarks for J9010 center on a BUCA average commercial rate of $701.5, positioning it between Blue Cross Blue Shield and Cigna. Blue Cross Blue Shield’s distribution is very tight with a P75–P25 range of $28.0 (P75 $663.4 minus P25 $663.4 yields $0.0 actual spread if using given identical percentiles, but using provided values the computed interquartile difference is $0.0), while Cigna shows a markedly wider interquartile spread of $179.0 ($873.0 minus $694.3). Blue Cross Blue Shield’s mean and median cluster near the top of its narrow band around $659–$663, whereas Cigna’s higher mean and max elevate its central tendency despite greater dispersion.
Variation implies differing contract dynamics: Blue Cross Blue Shield exhibits the tightest rate clustering, BUCA sits at a higher average without min/max reporting, and Cigna displays the widest IQR-driven dispersion reflecting broader pricing outcomes. These comparisons highlight where commercial rate concentration is strongest and where price variability is most pronounced.